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Radiochemistry in a flash: photochemical conjugation and one-
pot radiolabelling of antibodies for immuno-PET 
 
Malay Patra,[a]† Larissa S. Eichenberger,[a] Gregor Fischer[b] and Jason P. Holland*[a] 
 
Abstract: Monoclonal antibodies (mAbs), immunoglobulin fragments 
and other proteins are important scaffolds in the development of 
radiopharmaceuticals for diagnostic immuno-positron emission 
tomography (immuno-PET) and targeted radioimmunotherapy (RIT). 
Conventional methods for radiolabelling proteins with metal ions like 
68Ga, 64Cu, 89Zr, and 90Y etc require multi-step procedures involving 
pre-purification, functionalisation with a chelate, and subsequent 
radiolabelling. Standard coupling chemistries are time consuming, 
difficult to automate, and involve synthesis, isolation and storage of 
an intermediate, new molecular entity (the conjugated mAb) whose 
biochemical properties can differ from those of the parent protein. To 
circumvent these issues, we developed a photoradiochemical 
approach that uses fast, chemoselective, light-induced protein 
modification under mild conditions with novel metal ion binding 
chelates derivatised with arylazide (ArN3) groups. Experiments show 
that one-pot photochemical conjugation and radiolabelling of 
formulated mAbs can be achieved in <20 min.  
Classical methods for radiolabelling proteins usually involve 
multiple steps in which the protein is first purified, coupled to a 
metal binding chelate, isolated, stored, and then radiolabelled.[1] 
Many coupling chemistries exist, but in the clinic, most 
radiolabelled mAb production relies on modification of either 
cysteine (thiolate) resides using maleimido-based reagents, or 
functionalisation of the lysine -NH2 side-chain by using N-
hydroxysuccinimide (NHS) or isothiocyanate (NCS) reagents.[2] 
Modern routes that employ enzymatic coupling[3–5] or strain-
promoted alkene-alkyne ‘click’-based[6–8]  chemistry are 
advancing, but from a translational perspective, they present 
additional challenges for use in Good Manufacturing Processes.  
An ideal radiolabelling method should be simple, fast, and 
involve a single-step starting from well-characterised, stable 
precursors, with no isolated intermediates. As clinical 
radiopharmaceutical productions use high levels of radioactivity, 
full automation is desirable. Time constraints imposed by 
radioactive decay also mean that chemical kinetics are crucial in 
deciding if a new reaction is suitable for use in radiochemistry.[9] 
Taking these points into account, we postulated that 
photochemical methods could be an attractive alternative to 
thermochemical processes that are commonly used to radiolabel 
immunoglobulins, other proteins, peptides and small-molecules. 
Photoaffinity labelling (PAL) of proteins is well-established 
and a rich array of photoactivatable groups have been 
reported.[10–12] PAL reagents are often built around 
benzophenones, diazirines and substituted arylazides (ArN3). 
Irradiation with light ( ~200 to ~420 nm), generates radical, 
carbene or nitrene intermediates that have observed lifetimes in 
the picosecond (ps) to microsecond (s) range. Such extreme 
reactivity means that mechanistically, PAL usually requires pre-
association of the photoactive ligand with the target protein to 
avoid non-productive background reactions. Pre-formation of the 
non-covalent ligand-protein complex facilitates first-order 
intramolecular bond formation but restricts the standard PAL 
concept to systems that self-assemble. If reagents and conditions 
can be found whereby bimolecular coupling of a photo-induced 
intermediate to proteins occurs faster than background reactions, 
then photochemical conjugation could be generalised for a more 
wide-spread use in radiochemistry.  
Surprisingly few examples exist where experiments combined 
photochemistry with radiochemistry. In pioneering work, Sykes et 
al. used photoactivation of an antibody to generate reactive 
sulfhydryl groups which facilitated 99mTc and 188Re 
radiolabelling.[13,14] The same approach was also used by Stalteri 
and Mather.[15] Hashizume et al. prepared [18F]pentafluorophenyl 
azide via isotopic exchange.[16] Wester et al. reported that ultra-
violet irradiation of 4-azidophenacyl-[18F]fluoride ([18F]APF) gave 
radiolabelled proteins in ~15% to ~35% radiochemical yield 
(RCY).[17] Lange et al. used 3-azido-5-nitrobenzyl-[18F]fluoride to 
radiolabel an oligonucleotide aptamer.[18] Pandurangi et al. 
extended the concept to complexes of 109Pd, Re, and 99mTc.[19–22] 
Finally, Nishikawa et al. radiolabelled plasmid DNA with 111In 
using photoactivatable 4-(p-azidosalicylamido)butylamine 
diethylenetriaminepentaacetic acid (DTPA-ASBA).[23] Since these 
initial studies, photochemical methods have remained relatively 
untouched by radiochemists. 
Here, we show that photochemical conjugation can be used 
to radiolabel mAbs with 68Ga (t1/2 = 67.71 min.) via an ArN3-
functionalised chelate (NODAGA-PEG3-ArN3, compound 5, 
Scheme 1). The method works via a conventional two-step, pre-
conjugation and radiolabelling pathway, and also by a one-pot, 
pre-radiolabelling route. Remarkably, photochemical conjugation 
was successful using formulated antibody solutions (HerceptinTM), 
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without pre-purification of the mAb. The speed and simplicity of 
this photoradiochemical route renders the method suitable for 
automation. 
Insert Scheme 1 
Scheme 1. Photochemical conjugation and radiolabelling of antibodies. (Top) 
Conventional two-step pathway involving pre-conjugation and radiolabelling. 
(Bottom) One-pot pathway involving pre-radiolabelling then photochemical 
conjugation. (Centre) Simultaneous, one-pot photoradiochemical labelling. 
The photoactivatable ligand, NODAGA-PEG3-ArN3 (5) was 
synthesised in three steps via standard chemical transformations 
(overall yield 19.4%; Supporting Information Scheme S1, Figures 
S2 – S16). Para-substituted ArN3 was selected as the 
photoreactive group.[10,24] Irradiation of ArN3 releases N2(g) 
forming a singlet arylnitrene (1A2 ground state), which at room 
temperature undergoes extremely fast (k1 ~109 s-1; lifetime,  ~1 
ns) intramolecular rearrangement to give benzazirine or 
ketenimines intermediates.[25] Unlike the radical or carbene 
species produced from irradiation of benzophenones and 
diazirines, respectively, ketenimines react relatively slowly with 
oxygen, protons and water, but undergo rapid nucleophilic 
addition with primary or secondary amines.[26,27] Thus, substituted 
arylazides are a suitable starting point for developing bimolecular 
photoradiochemistry. 
Compound 5 readily formed coordination complexes with 
natGa3+ and radioactive 68Ga3+ ions (Figures S17 – S20). Both the 
free ligand (5) and metal complexes (nat/68Ga-5) were found to 
react upon irradiation with three different light sources (max ~365 
nm; Figures S21 – S23). The rate of photodegradation of 
compounds 5 and nat/68Ga-5 was proportional to light intensity and 
obeyed the anticipated first-order kinetics with, in each case, one 
major product observed by high-performance liquid 
chromatogram (HPLC). High-resolution mass spectrometry 
confirmed that irradiation of compound 5 led to the formation of 
NODAGA-PEG3-azepin-2-ol which was likely produced via 
reaction between the photo-induced intermediates and water. 
After confirming that compound 5 and nat/68Ga-5 were 
photoactive, trastuzumab (isolated by size-exclusion 
chromatography [SEC] from HerceptinTM) was pre-incubated with 
the ligand, irradiated for 30 min. at room temperature, re-purified, 
and then radiolabelled with [68Ga][Ga(H2O)6]Cl3(aq.) under 
standard conditions. After reaction, the crude mixture was purified 
by preparative PD-10-SEC methods. Aliquots of the crude and 
purified samples were analysed by radioactive-instant thin-layer 
chromatography (radio-iTLC), analytical PD-10-SEC, and by 
SEC-ultra high-performance liquid chromatography (SEC-
UHPLC; Figure 1, Table S1). Even though the photochemical step 
was performed under non-optimised conditions, radiolabelling of 
NODAGA-azepin-trastuzumab was complete in <15 min. giving 
[68Ga]GaNODAGA-azepin-trastuzumab in a radiochemical 
conversion  >98% (RCC; n = 6), a molar activity Am of 16.3  4.1 
MBq/nmol (n = 8), and a final radiochemical purity of >98% by 
SEC-UHPLC. Starting from a 50-fold molar excess of chelate with 
respect to protein in the photochemical step, the measured 
accessible chelate-to-mAb ratio in the radiolabelled product was 
0.39  0.10 (n = 8). Control reactions confirmed that no non-
specific binding occurred between 68Ga3+ ions and the mAb. 
Trastuzumab was also stable under the photochemical 
conjugation and radiolabelling conditions (Figures S24 – S26). 
Insert Figure 1 
Figure 1. Characterisation data for the radiochemical synthesis of 
[68Ga]GaNODAGA-azepin-trastuzumab. (A) Radio-iTLC chromatograms, (B) 
analytical PD-10-SEC elution profiles, and (C) SEC-UHPLC chromatograms of 
the crude and purified product. 
Next, we optimised conditions for the photochemical 
conjugation between compound 5 and trastuzumab. As the 
conjugation mechanism relies on the nucleophilicity of an amine, 
the reaction pH was adjusted between 4.5 – 9.5 using NaHCO3. 
Radiolabelling of crude photochemically coupled samples and 
subsequent chromatographic analyses showed that the RCC 
increased from ~1.0% at pH4.5 to ~17.8% at pH8.5 (Table S2, 
Figure S27). Further tests showed that with increasing light 
intensity, the photochemical conjugation step could be reduced 
<5 min. without compromising reaction efficiency. Also, with 
efficient mixing, the radiolabelling step was complete in <5 min. 
The final chelate-to-antibody ratio was reassessed after 
photochemical conjugation at pH8.5 and a linear relationship was 
found between the measured number of accessible chelates 
bound to the mAb and the initial chelate-to-mAb ratio (Table S3, 
Figure S28). Assuming that all accessible chelates were 
radiolabelled, and using the RCC and the measured fraction of 
photoreacted starting material, the photochemical conjugation 
efficiency for trastuzumab functionalisation with compound 5 was 
estimated to be r = 0.351 (equivalent to a reaction quantum yield). 
Most efficient thermochemical coupling methods have yields in 
the range 30% – 80%[28–30] which makes the photochemical route 
competitive with existing technology.  
The reaction was then scaled up and the product was 
subjected to standard chemical and biochemical tests in vitro. 
Using an initial chelate-to-mAb ratio of 5:1, [68Ga]GaNODAGA-
azepin-trastuzumab in sterile PBS was prepared in a decay 
corrected RCY of 80.1  4.1%, with RCP >98%, and a molar 
activity, Am of 38.4  0.7 MBq/nmol (Figure S29). Stability tests 
showed no change in RCP after incubating the product in excess 
EDTA or in human serum at 37 oC for >2 h (Figures S30 – S31, 
Table S4). Saturation binding (Lindmo) assays using SK-OV-3 
cells (HER2/neu positive) also confirmed that [68Ga]GaNODAGA-
azepin-trastuzumab was biochemically viable with an 
immunoreactive fraction of 70.7  4.9%, which is comparable to 
previous reports on radiolabelled trastuzumab (Figure S32).[30] 
PET imaging and biodistribution experiments were then 
performed in athymic nude mice (n = 4 animals/group) bearing 
subcutaneous SK-OV-3 tumours to measure the pharmacokinetic 
(PK) profile and binding specificity of [68Ga]GaNODAGA-azepin-
trastuzumab in vivo (Figure 2, Figures S33 – S38, Table S5). 
Measurements of total radioactivity in the animals found that the 
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trastuzumab was 68.0  1.8 min., equivalent to the physical half-
life of the radionuclide and consistent with the expected PK profile 
of radiolabelled mAbs (Figure S39).[30] Temporal PET imaging 
revealed that [68Ga]GaNODAGA-azepin-trastuzumab remained 
in circulation for >6 h post-injection with most activity visible in the 
blood pool component of the heart. Tumours of the normal group 
of animals were readily visualised by PET. Competitive binding 
studies using co-injection of a blocking dose of non-radiolabelled 
trastuzumab (low molar activity formulation, Am of 1.85  0.01 
MBq/nmol of protein) confirmed that tumour uptake was specific 
and that the product remained biologically active in vivo. 
Biodistribution analysis ex vivo corroborated the PET data and 
found radioactivity accumulation of 16.5  1.0 %ID/g in the normal 
tumours compared with 8.9  1.1 %ID/g in tumours of the blocking 
group (Student’s t-test P-value < 0.001). 
Insert Figure 2 
Figure 2. [68Ga]GaNODAGA-azepin-trastuzumab PET images recorded in mice 
bearing SK-OV-3 tumours on the right flank. T = tumour, H = heart, L = liver, Sp 
= spleen. 
Encouraged by the results, we tested the photoradiochemical 
reaction further by using a one-pot approach. Compound 5 was 
pre-radiolabelled with 68Ga, re-buffered to pH ~8.0, mixed with 
pre-purified trastuzumab and then irradiated (Figure 3). Analytical 
methods confirmed that the one-pot pre-radiolabelling approach 
could be completed in <20 min. total time (including radiolabelling, 
photochemical conjugation and purification) to give 
[68Ga]GaNODAGA-azepin-trastuzumab in sterile PBS with a 
decay corrected RCY of 33.9  0.7% (n = 3). Development of this 
fast and efficient one-pot route simplifies the production of 
radiolabelled proteins by removing the need to synthesise, isolate 
and store the pre-functionalised intermediate under GMP 
conditions. In addition, the one-pot route can be automated easily 
using modular radiosynthesis units. 
Insert Figure 3 
Figure 3. Characterisation data for the one-pot photoradiochemical synthesis 
of [68Ga]GaNODAGA-azepin-trastuzumab from pre-purified mAb. (A) Radio-
iTLC chromatograms, (B) analytical PD-10-SEC elution profiles, and (C) SEC-
UHPLC chromatograms of the crude and purified product. 
Finally, the one-pot photoradiochemistry approach was tested 
using fully formulated HerceptinTM (i.e. non-purified trastuzumab). 
Clinical preparations of antibodies are typically stabilised by the 
addition of salts, amino acids, anti-oxidants and surfactants. 
HerceptinTM contains histidine, ,-trehalose dehydrate and 
polysorbate 20. Traditional coupling methods do not tolerate such 
additives which necessitates pre-purification of the mAb (usually 
from a GMP source). Removing the stabilisers risks damaging the 
protein, and isolation/storage of an intermediate species raises 
concerns regarding the long-term biological integrity of the 
radiolabelling precursor with respect to the parent compound. 
Methods that allow direct radiolabelling of the formulated GMP-
grade mAbs could potentially redefine the way in which 
radiopharmaceuticals are prepared for immuno-PET and RIT. 
Experiments showed that the photoradiochemical approach using 
HerceptinTM produced [68Ga]GaNODAGA-azepin-trastuzumab in 
a decay-corrected RCY of 23.3  3.4% (n = 3, Figure S40). 
Interestingly, histidine had only a small impact on the RCY. 
Additional experiments also confirmed that the one-pot approach 
was applicable for radiolabelling other proteins including a scFv-
Fc fragment and human serum albumin (Figure S41). 
From a pharmacokinetic standpoint, the combination of 68Ga 
with long-circulating, full-length mAbs is sub-optimal but this 
radionuclide confirms the proof-of-concept and is useful for 
radiolabelling lower molecular weight species like immunoglobulin 
fragments and peptides. Compound 5 can also form complexes 
with other radionuclides including 64Cu. Based on data reported 
here, we have expanded the approach by synthesising a range of 
photoactivatable chelates for radiolabelling with 64Cu, 89Zr, 90Y, 
111In, 177Lu, 225Ac and others. For systems where the pH window 
for radiolabelling is >7 - 8 (for example, [89Zr][Zr(C2O4)4]4-(aq.) 
complexation by desferrioxamine B [DFO]), a simultaneous 
photoradiochemical process is feasible (Scheme 1). Experiments 
continue to investigate the effects of linker modification and ArN3 
substitution on bimolecular photochemical conjugation efficiency, 
as well as chemical scope of photoradiochemistry using 
immunoglobulin fragments, proteins, peptides, nanoparticles and 
small-molecules. 
Experimental Section 
Full experimental details and characterisation data are provided 
in the Supporting Information. 
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